Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 3

Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis

Authors Michelon MA, Gottlieb A

Published 25 May 2010 Volume 2010:3 Pages 79—84

DOI https://doi.org/10.2147/CCID.S6186

Review by Single-blind

Peer reviewer comments 3


Melissa A Michelon1, Alice B Gottlieb1,2

1Tufts University School of Medicine, 2Department of Dermatology, Tufts Medical Center, Boston, MA, USA

Abstract: Psoriatic arthritis (PsA) is an inflammatory arthritis that affects many psoriasis patients and can often have a debilitating disease progression. Golimumab is a new tumor necrosis factor (TNF) antagonist recently approved by the FDA for controlling signs and symptoms of psoriatic arthritis. In a Phase III clinical trial in patients with PsA, patients receiving golimumab showed significant improvement in the signs and symptoms of disease. It was usually well tolerated, but adverse events generally occurred more in patients receiving golimumab compared to placebo. Golimumab has also recently shown efficacy in slowing structural damage in PsA. This new biologic therapy provides physicians with another option in the treatment of this inflammatory arthritis while offering patients certain advantages over other TNF antagonists.
Keywords: golimumab, psoriatic arthritis, TNF-alpha inhibitor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]